

- 1- Wald N, Sneddon J, Densem J, Frost C, Stone R, MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. *Lancet* 1991;338:131–7.
- 2- Reece EA, Khandelwal M, Wu YK, Borenstein M. Dietary intake of myo-inositol and neural tube defects in offspring of diabetic rats. *Am J Obstet Gynecol* 1997;176:536–9.
- 3- Greene NDE, Copp AJ. Inositol prevents folate-resistant neural tube defects in the mouse. *Nat Med* 1997;3:60–6.
- 4- Ting SB, Wilanowski T, Auden A, Hall M, Voss AK, Thomas T, Parekh V, Cunningham JM, Jane SM. Inositol and folate-resistant neural tube defects in mice lacking the epithelial-specific factor Grhl-3. *Nat Med* 2003;9(12):1513-9
- 5- Groenen PM, Peer PG, Wevers RA, Swinkels DW, Franke B, Mariman EC, Steegers-Theunissen RP. Maternal myo-inositol, glucose, and zinc status is associated with the risk of offspring with spina bifida. *Am J Obstet Gynecol* 2003; 189(6):1713-9
- 6 - Cavalli P, Copp AJ. Inositol and folate resistant neural tube defects. *J Med Genet.* 2002 Feb;39(2):E5
- 7- Cavalli P, Tedoldi S, Riboli B. Inositol supplementation in pregnancies at risk of apparently folate-resistant NTDs. *Birth Defects Res A Clin Mol Teratol.* 2008 Jul;82(7):540-2.
- 8- Cavalli P, Tonni G, Grosso E, Poggiani C. Effects of inositol supplementation in a cohort of mothers at risk of producing an NTD pregnancy. *Birth Defects Res A Clin Mol Teratol.* 2011 Sep 28
- 9 - Phaneuf S, Europe-Finner GN, Carrasco MP, Hamilton CH, Lopez Bernal A. Oxytocin signalling in human myometrium. *Adv Exp Med Biol.* 1995;395:453-67
- 10- Van der Put NMJ, Steegers-Theunissen RPM, Frosst P, Trijbels FJM, Eskes TKAB, Van den Heuvel LP, Marimah ECM, Den Heyer M, Rozen R, Blom HJ. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. *Lancet* 1995;346:1070–1.
- 11- Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H, Gravel RA, Rozen R. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. *Mol Genet Metab.* 1999; 67(4):317-23
- 12- Seller MJ. Recurrence risks for neural tube defects in a genetic counselling clinic population. *J Med Genet* 1981;18:245–8.
- 13- Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. *Am J Psychiatry* 1995; 152:1084–6.
- 14- Colodny L, Hoffman RL. Inositol—clinical applications for exogenous use. *Altern Med Rev* 1998;3:432–47
- 15- Wald NJ, Law MR, Morris JK, Wald DS. Quantifying the effect of folic acid. *Lancet* 2001; 358(9298):2069-73
- 16- Cogram P, Hynes A, Dunlevy LP, Greene ND, Copp AJ. Specific isoforms of protein C kinase are essential for prevention of folate-resistant neural tube defects. *Hum. Mol Genet.* 2004; 13(1):7-114
- 17- Cogram P, Tesh S, Tesh J, Wade A, Allan G, Greene NDE, Copp AJ. D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects. *Hum Reprod* 2002; 17:2451-2458
- 18- Shaw GM, Carmichael SL, Yang W, Schaffer DM. Periconceptional dietary intake of myo-inositol and neural tube defects in offspring. *Birth Defects Research Part A* 2005;73(3):184-7